论文部分内容阅读
目的探讨α硫辛酸联合甲钴胺应用于糖尿病周围神经病变(diabeitc peripheral neuropathy,DPN)治疗的临床疗效。方法选取2010-02—2015-01我院收治的80例糖尿病神经病变患者为研究对象,采用随机数字表法随机分为观察组与对照组,均给予降血糖、降脂及降压治疗,对照组给予甲钴胺治疗,观察组给予α硫辛酸联合甲钴胺治疗,对2组的临床疗效、治疗前后密西根糖尿病性周围神经病评分(MDNS)及神经传导速度进行对比。结果观察组与对照组的总有效率分别为97.50%、60.00%,观察组总有效率显著升高,差异有统计学意义(P<0.01);与治疗前对比,2组患者治疗后腓总神经、正中神经、胫神经的感觉神经的传导速度及运动神经的传导速度均显著加快,治疗后,与对照组对比,观察组神经传导速度加快更显著,差异有统计学意义(P<0.05);与治疗前对比,观察组患者的MDNS评分显著下降,对照组患者的MDNS评分无显著变化;治疗后与对照组对比,观察组患者MDNS评分显著降低,差异有统计学意义(P<0.05)。结论α硫辛酸联合甲钴胺应用于DPN的治疗疗效显著,显著加快神经传导速度病改善患者症状及体征,值得临床推广应用。
Objective To investigate the clinical efficacy of α-lipoic acid combined with mecobalamin in the treatment of diabetic peripheral neuropathy (DPN). Methods Totally 80 diabetic neuropathy patients admitted to our hospital from February 2010 to May 2015 were selected and randomized into observation group and control group. All patients were given hypoglycemic, lipid-lowering and antihypertensive treatment. The patients in the observation group were given α-lipoic acid combined with mecobalamin. The clinical efficacy, the MDNS and the nerve conduction velocity before and after treatment in the two groups were compared. Results The total effective rates of the observation group and the control group were 97.50% and 60.00%, respectively, and the total effective rate in the observation group was significantly increased (P <0.01). Compared with those before treatment, the total effective rate Nerve, median nerve and tibial nerve sensory nerve conduction velocity and motor nerve conduction velocity were significantly accelerated after treatment, compared with the control group, the observation group nerve conduction velocity accelerated more significantly, the difference was statistically significant (P <0.05) Compared with the control group, the MDNS score of the observation group decreased significantly (P <0.05), and the MDNS score of the observation group had no significant difference . Conclusion The application of alpha-lipoic acid combined with mecobalamin has a significant therapeutic effect on DPN, which significantly accelerates the improvement of symptoms and signs of patients with neurotransmitter-speed disease and deserves clinical application.